Increase in plasma esterified F2-isoprostanes following intravenous iron infusion in patients on hemodialysis

Kidney International

Volumn 60, Issue 4, 2001, Pages 1525-1531

  Salahudeen, A K ^a   Oliver, B ^a   Bower, J D ^a   Roberts II, L J ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

Anemia; Atherogenesis; Dialysis; Epoetin; Free iron; Lipid peroxidation; Proinflammation; Redox iron; Transferrin saturation

Indexed keywords

ANTIOXIDANT; FERRITIN; IRON; IRON DEXTRAN; ISOPROSTANE DERIVATIVE; LIPID; LIPOPROTEIN; TRANSFERRIN;

ADULT; ANEMIA; ARTICLE; ARTIFACT; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; ESTERIFICATION; FEMALE; FERRITIN BLOOD LEVEL; GAS CHROMATOGRAPHY; HEMODIALYSIS; HOME DIALYSIS; HUMAN; IRON BLOOD LEVEL; LIPID PEROXIDATION; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; PROSPECTIVE STUDY;

EID: 0034796902     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2001.00976.x     Document Type: Article

References (40)

1. "Oversaturation" of transferrin after intravenous ferric gluconate (Ferrlecit(R)) in haemodialysis patients
2. Vitamin E attenuates oxidative stress induced by intravenous iron in patients on hemodialysis
3. Cellular and molecular studies of atherogenesis
4. Atherosclerosis: An inflammatory disease
5. Patient mortality and survival: USRDS
6. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin
7. Lipid peroxidation: Its mechanism, measurement, and significance
8. Pathophysiologic modulation of arachidonate metabolism
9. Measurement of F(2)-isoprostanes as an index of oxidative stress in vivo
10. A series of prostaglandin F2-1ike compounds are produced in vivo in humans by a noncyclooxygenase, free radical-catalyzed mechanism
11. Non-cyclooxygenase-derived prostanoids (F2-isoprostanes) are formed in situ on phospholipids
12. F2-Isoprostanes and the kidney
13. The isoprostanes: Unique bioactive products of lipid peroxidation
14. Formation of F2-isoprostanes during the oxidation of human low density lipoprotein by peroxynitrite
15. Comparison of methods used to measure serum iron in the presence of iron gluconate or iron dextran
16. Mass spectrometric quantification of F2-isoprostanes in biological fluids and tissues as a measure of oxidant stress
17. Oxidants and antioxidants in the pathogenesis of atherosclerosis: Implications for the oxidized low density lipoprotein hypothesis
18. The role of oxidized LDL in atherogenesis: Immunological response and anti-phospholipid antibodies
19. Oxidative modification of LDL and atherogenesis
20. Iron and the sex difference in heart disease risk
21. High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men
22. Iron overload augments the development of atherosclerotic lesions in rabbits
23. Body iron stores and presence of carotid atherosclerosis. Results from the Bruneck Study
24. Low iron-binding capacity as a risk factor for myocardial infarction
25. Prevalence of hereditary haemochromatosis in premature atherosclerotic vascular disease
26. Lack of association between ferritin level and measures of LDL oxidation: The ARIC study. Atherosclerosis Risk in Communities
27. Association between body iron stores and the risk of acute myocardial infarction in men
28. Optimization of an enzyme immunoassay for 11-dehydro-thromboxane B(2) in urine: Comparison with GC-MS
29. The efficacy of iron dextran for the treatment of iron deficiency in hemodialysis patients
30. Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients
31. Anemia and iron target realization in 1998: Clinical Practice pattern in 1659 patients on hemodialysis
32. Anemia management of adult hemodialysis patients in the U.S.: Results from the 1997 ESRD cote indicators project
33. NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure: National Kidney Foundation-Dialysis Outcomes Quality Initiative
34. C282Y mutation in the HLA-H gene is not a risk factor for patients with myocardial infarction
35. Acute iron poisoning. A review
36. Oxidant stress in hemodialysis: Prevention and treatment strategies
37. Oxidative stress and haemodialysis: Role of inflammation and duration of dialysis treatment
38. Markers of oxidative damage and antioxidant protection: Assessment of LDL oxidation
39. Formation of F2-isoprostanes during oxidation of human low-density lipoprotein and plasma by peroxynitrite